Inner Banner

Five-Year Patient-Reported Outcomes for Various Prostate Cancer Treatments

A 5-year follow-up study of more than 2,000 U.S. men who received prostate cancer treatment—radiation, surgery, or active surveillance—in patients of all ages a..

2/15/2020 865 read more

ADMIRAL Trial: More Than Standard Chemotherapy Needed for FLT3-Mutant Advanced AML

The important ADMIRAL trial, reported by Perl et al in The New England Journal of Medicine1 and reviewed in this issue of The ASCO Post, shows the efficacy of a..

2/15/2020 1 read more

Avelumab Maintenance Does Not Provide Superior OS Compared With Standard Chemo in Advanced Gastric/G..

The PD-L1 immune checkpoint inhibitor failed to show a superior improvement in overall survival (OS) in comparison with standard chemotherapy both in the overal..

2/9/2020 18 read more

Concurrent Durvalumab/RT Plus Adjuvant Durvalumab in Locally Advanced Urothelial Cancer of Bladder

Monika Joshi, MD, MRCP, associate professor of medicine, Division of Hematology-Oncology, and co-leader for Genitourinary Disease Team, at Penn State Hershey Ca..

2/9/2020 802 read more

Cabozantinib and Atezolizumab Combo Has Synergistic Activity in Metastatic CRPC

Combining cabozantinib (Cabmetyx) and atezolizumab (Tecentriq) induced durable responses in men with metastatic castration-resistant prostate cancer (CRPC) who ..

2/9/2020 848 read more

Regorafenib Plus TAS-102 Clinically Meaningful Disease Control in mCRC

The combination of regorafenib (Stivarga) plus an oral fluoropyrimidine, TAS-102, (trifluridine/tipiracil; Lonsurf), as third-line treatment in patients with me..

2/9/2020 945 read more